Nuclear receptors as therapeutic targets in cholestatic liver diseases.
about
Q24186229Bile acids: regulation of synthesisBile acid metabolism and signalingHepatic osteodystrophySmall Molecule Agonists of the Orphan Nuclear Receptors Steroidogenic Factor-1 (SF-1, NR5A1) and Liver Receptor Homologue-1 (LRH-1, NR5A2)The role of inflammation in cholestasis: clinical and basic aspectsBile acid signaling in metabolic disease and drug therapyCoordinated Actions of FXR and LXR in Metabolism: From Pathogenesis to Pharmacological Targets for Type 2 DiabetesConstitutive androstane receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier.Transcription factor Nrf2 regulates SHP and lipogenic gene expression in hepatic lipid metabolism.Differential Sympathetic Vasomotor Activation Induced by Liver Cirrhosis in Rats.Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.Bcl2 is a critical regulator of bile acid homeostasis by dictating Shp and lncRNA H19 function.Immunogenomics reveal molecular circuits of diclofenac induced liver injury in miceEffects of three different fibrates on intrahepatic cholestasis experimentally induced in rats.Alternatives to animal experimentation for hormonal compounds researchBile acids modulate signaling by functional perturbation of plasma membrane domains.Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases.The impact of cholesterol and its metabolites on drug metabolism.Targeting nuclear bile acid receptors for liver disease.Bile acid transporters and regulatory nuclear receptors in the liver and beyondPrimary sclerosing cholangitis: a review and update on therapeutic developments.Vitamin D in chronic liver disease.Hepatic expression of multidrug resistance protein 2 in biliary atresia.Transcriptional changes in African clawed frogs (Xenopus laevis) exposed to 17α-ethynylestradiol during early development.A shift in paradigm towards human biology-based systems for cholestatic-liver diseases.The human UGT1A3 enzyme conjugates norursodeoxycholic acid into a C23-ester glucuronide in the liver.Importance of detoxifying enzymes in differentiating fibrotic development between SHRSP5/Dmcr and SHRSP ratsNew insights on the pathogenesis of biliary cirrhosis provided by studies in FXR knockout miceThe arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism.Targeting H19, an Imprinted Long Non-Coding RNA, in Hepatic Functions and Liver DiseasesAssociation of Antituberculosis Treatment and Lower Risk of Hyperlipidemia in Taiwanese Patients: A Population-Based Case-Control Study.Effects of corilagin on alleviating cholestasis via FXR-associated pathways in vitro and in vivo.Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis.Persisting hyperbilirubinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with eculizumab: The role of hepatocanalicular transporter variants.Disrupted Murine Gut-to-Human Liver Signaling Alters Bile Acid Homeostasis in Humanized Mouse Liver Models.Pravastatin modulates liver bile acid and cholesterol homeostasis in rats with chronic cholestasis.Association of genes involved in bile acid synthesis with the progression of primary biliary cirrhosis in Japanese patients.Characterization and treatment of persistent hepatocellular secretory failureEssential roles of bile acids and their nuclear receptors, FXR and PXR, in the cholestatic liver disease
P2860
Q24186229-0821B0A2-A034-4131-9AF2-13F2A0E689C8Q24658139-4F5B2073-71A6-456D-8D45-97BCBAB0D56FQ27002873-BA1FFF99-B823-40AE-9243-2CC81C3E734AQ27004571-8F0008CC-9595-41AA-9D74-481F9012B4E6Q27667247-17136743-17DE-40B6-8616-1859B22FBA3CQ27694662-5C5C78C7-F645-4995-BA33-030570B551AEQ28244875-2E354FD2-0166-4D25-AD39-FB5B86802A89Q33608251-DF5D5A64-2E41-47C2-BA7B-D3919A2CD56DQ34128009-6525A9A1-A7D9-46E4-A78A-70F3CB61D310Q34425926-CC67CEC8-A40C-424E-948E-5E72F5D03F9CQ35982690-FD9B2823-4F52-40B6-898C-EBF10C4641B1Q36197335-9A46C2DB-CBD8-4B2F-92CC-E11095A0B6A9Q36536495-5E05997F-8726-4BE4-887B-F75B958311B2Q37046776-8961F7BC-095F-4CCA-B2CE-EC1CC61C0714Q37122494-25817A4C-F58C-477A-A821-4772D3D73129Q37350782-6AB1C2A0-1B61-4247-A80D-0D78F056AC54Q37388767-1380DC49-D497-4645-B129-B5C056FD4531Q37702088-03366AB8-20AD-4632-B4A5-236B6030E232Q37841609-B87078B4-18F7-42DB-B72C-B96880A95716Q37892293-D28365F5-75A0-4A03-A11C-78DC4C011661Q38033967-CEECB79D-F519-4E53-AAD1-8E5CCE2A5F74Q38077820-1953997C-822C-4426-B941-75A75E6C3053Q38080943-35A2E441-782B-4343-9FDC-C5269A6290BCQ38261468-E778C01B-12A0-4DDE-8E5C-AB9A8A682F44Q38415462-D5C1C67E-F5BD-4E44-B809-D9F6CD06E9DFQ38595049-DE4DAA2C-BDD0-41DD-B678-702B1D083AC2Q39779007-CEBA9691-6EB6-45F9-A194-3697B21713D0Q41885280-8531EBC5-BCF3-4874-BDCA-A4383CCB4F14Q42083872-8384DA1E-B99F-4A15-92B3-E1A1DEBCB477Q42096573-49B3FB54-235F-4E0D-B2D4-52E97CCDAA3DQ42226751-FA1ED96D-7F81-4D93-B0F5-C14766638C54Q47221266-52F43EA8-B2AA-4DEF-B803-D68F1BDEBC3EQ47299438-3F8F1EB1-CF2D-4789-A332-DA3A2D30F98EQ47668921-2B668E1B-B223-437E-8FA1-C75F8C3735B6Q48152299-59AF64DE-B202-4986-9ACF-217EE704E284Q48453320-C75C0888-A063-4329-BCF0-5203C4B837A2Q50066253-F367D6C7-EBB9-4289-9509-B77CE5266110Q54274187-92D68743-2820-411E-880B-DF73B426F11EQ57145981-780F7B07-6532-4AA9-89C3-E9F8125928F2Q58133950-2F3CAB9C-49D4-4A89-BF42-68B2BE4C321F
P2860
Nuclear receptors as therapeutic targets in cholestatic liver diseases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Nuclear receptors as therapeutic targets in cholestatic liver diseases.
@en
Nuclear receptors as therapeutic targets in cholestatic liver diseases.
@nl
type
label
Nuclear receptors as therapeutic targets in cholestatic liver diseases.
@en
Nuclear receptors as therapeutic targets in cholestatic liver diseases.
@nl
prefLabel
Nuclear receptors as therapeutic targets in cholestatic liver diseases.
@en
Nuclear receptors as therapeutic targets in cholestatic liver diseases.
@nl
P2860
P1476
Nuclear receptors as therapeutic targets in cholestatic liver diseases
@en
P2093
Michael Trauner
P2860
P356
10.1111/J.1476-5381.2008.00030.X
P407
P577
2009-01-01T00:00:00Z